Skip to main content
Midas Edge

Prime Medicine Inc

For the period ended Dec 31, 2024. Filed Feb 28, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 28, 2025

PRME$3.90-9.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity F-

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders' Equity
(in thousands, except share amounts) · Shares · Amount
Balances at December 31, 202297,209,213$2$609,849$(384)$(293,197)$316,270
Issuance of common stock upon exercise of stock options167,908—655——655
Stock-based compensation expense——13,910——13,910
Change in unrealized loss on investments, net of tax———369—369
Net loss————(198,133)(198,133)
Balances at December 31, 202397,377,121$2$624,414$(15)$(491,330)$133,071
Issuance of common stock from public offering, net of issuance costs of $8.9 million22,560,001—132,055——132,055
Issuance of pre-funded warrants, net of issuance costs of $1.2 million——18,800——18,800
Issuance of common stock under the Securities Purchase Agreement to BMS — related party (Note 9)11,006,163—38,081——38,081
Issuances of common stock under the employee stock purchase plan189,509—837——837
Issuances of common stock upon exercise of stock options28,048—103——103
Stock-based compensation expense——26,068——26,068
Change in unrealized loss on investments, net of tax———16—16
Net loss————(195,882)(195,882)
Balances at December 31, 2024131,160,842$2$840,358$1$(687,212)$153,149
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.